Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIO-1: Lucitanib plus Nivolumab in Advanced Metastatic Solid Tumors
2019-002980-81Phase 2Terminated
- Sponsor
- Clovis Oncology
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lucitanib and nivolumab in Nonhematologic neoplasms and gynecological cancer, sponsored by Clovis Oncology. Primary endpoint: Confirmed best overall response (PR or CR). Started Sep 2020; status: terminated.
02
Drugs
lucitanibnivolumab
03
Conditions
Nonhematologic neoplasmsgynecological cancer
Beyond the preview
Go deeper on 2019-002980-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002980-81.